Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01666080 · ClinicalTrials.gov registry record · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
A NA study of Hemoglobinopathies and Immunodeficiencies, sponsored by Masonic Cancer Center, University of Minnesota.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT01666080: Recruiting NA study of Hemoglobinopathies and Immunodeficiencies, sponsored by Masonic Cancer Center, University of Minnesota.
NCT01666080 is a NA study of Hemoglobinopathies and Immunodeficiencies that is actively recruiting participants, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 30 participants, below the 1,802-participant average among 17 other Hemoglobinopathies trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01666080, a NA study of Hemoglobinopathies and Immunodeficiencies, is actively recruiting participants, sponsored by Masonic Cancer Center, University of Minnesota.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a treatment guideline for a second or greater allogeneic hematopoietic stem cell transplant (HSCT) using a reduced intensity conditioning (RIC) in patients with non-malignant or malignant diseases. This regimen, consisting of busulfan, fludarabine, and low dose total body irradiation (TBI), is designed to promote engraftment in patients who failed to achieve an acceptable level of donor-derived engraftment following a previous allogeneic HCT.
Primary Outcome
Neutrophil engraftment is defined as the first day of three consecutive days where the neutrophil count (absolute neutrophil count) is 500 cells/mm3 (0.5 x 109/L) or greater.
Conditions Studied
Interventions
- DRUG Fludarabine
- DRUG Busulfan
- RADIATION Total body irradiation
- BIOLOGICAL Stem cell transplant
- DRUG Keppra
Study Locations (1)
Minnesota
- Masonic Cancer Center, University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2012-08 |
| Est. Completion | 2027-06 |
| Phase | NA |
What NCT01666080 shows while recruiting
NCT01666080 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,802-participant average among 17 other Hemoglobinopathies trials with a reported enrollment target (98% lower).
The record links to 3 conditions, with Hemoglobinopathies appearing as the primary indexed condition, and to 5 interventions - of which Fludarabine is the first listed.
NCT01666080 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT01666080 about?
NCT01666080 is a clinical study titled "Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)". This is a treatment guideline for a second or greater allogeneic hematopoietic stem cell transplant (HSCT) using a reduced intensity conditioning (RIC) in patients with non-malignant or malignant diseases. This regimen, consisting of busulfan, fludarabine, and low dose total body irradiation (TBI), ...
What is the current status of trial NCT01666080?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2012-08. Estimated completion is 2027-06.
What conditions does trial NCT01666080 study?
This clinical trial studies the following conditions: Hemoglobinopathies, Immunodeficiencies, Hematologic Disorders.
What interventions are being tested in trial NCT01666080?
The interventions under investigation include: Fludarabine (DRUG), Busulfan (DRUG), Total body irradiation (RADIATION), Stem cell transplant (BIOLOGICAL), Keppra (DRUG).
Who is sponsoring clinical trial NCT01666080?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01666080 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hemoglobinopathies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01666080's enrollment target sits among peer trials
30 8th of 17 higher than 10 of 17 other Hemoglobinopathies trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hemoglobinopathies trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion
ACTIVE NOT RECRUITING · NA
-
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
RECRUITING · Phase 1
-
Allo HSCT for High Risk Hemoglobinopathies
RECRUITING · Phase 2
-
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
RECRUITING · Phase 1
-
Study of the Role of Genetic Modifiers in Hemoglobinopathies
RECRUITING
-
Discarded Bone Marrow for Hematology Research
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
- NCT01894802 · 30 participants · NA
Cortical Recording and Stimulating Array Brain-Machine Interface
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia